Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
801-820 of 998 trials

Chronic Hypertension in Pregnancy: Aspirin Study

We are investigating whether low-dose aspirin can help prevent serious complications in pregnant women with chronic hypertension. This includes risks like preeclampsia and preterm delivery.

Pregnancy-Related Hypertension and Pre-Eclampsia6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine

Multifocal Motor Neuropathy: Empasiprubart vs. IVIg

We are studying whether Empasiprubart can improve muscle strength and function in adults with Multifocal Motor Neuropathy compared to standard IVIg treatment.

Multifocal Motor Neuropathy>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Clebopride for the Treatment of Rumination Syndrome

We are studying whether clebopride can improve symptoms in people suspected of having rumination syndrome. The trial compares its effects to a placebo to see how well it works.

Rumination Syndrome≤3 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Bipolar Disorder: Low-Dose Aspirin Study

We are investigating whether adding low-dose aspirin to standard treatment helps improve symptoms in patients with bipolar disorder. This study aims to assess both the effectiveness and safety of this approach.

Bipolar Disorder1-2 yearsEfficacy phase (II)Standard MedicinesPartially RemotePsychiatry

Advanced Solid Tumors: BMS-986482 Study

We are investigating the safety and dosage of BMS-986482 alone or with other therapies for patients with advanced solid tumors. This study aims to understand how well it works in combination with existing treatments.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Primary Sjögren's Disease: Efgartigimod Treatment Study

We are testing a new medication, efgartigimod, for adults with Primary Sjögren's Disease to see if it helps reduce disease activity and improve symptoms compared to a placebo.

Sjögren's Syndrome>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Immune-Related Rheumatological Events in Cancer Patients

We are collecting data on how to better diagnose and manage joint and muscle issues caused by cancer treatments. This study involves multiple centers to improve care for patients receiving checkpoint inhibitors.

Cancer (all types)>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyRheumatology

Cardiovascular Health in Type 2 Diabetes: COLCOT-T2D Study

We are studying whether colchicine and non-enteric coated aspirin can improve heart health in high-risk adults with type 2 diabetes. The goal is to see if these treatments can reduce serious heart-related events.

Unspecified Cardiovascular DiseaseConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteCardiologyEndocrinology

Pain Medication Tapering for Persistent Spinal Pain

We are studying how different methods of reducing pain medication affect disability in patients with Persistent Spinal Pain Syndrome Type II after spinal cord stimulation. This research may help improve pain management strategies.

Persistent Spinal Pain Syndrome Type II1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurologyOrthopedics and Traumatology

Maridebart Cafraglutide for Heart Failure and Obesity

We are studying whether maridebart cafraglutide can improve heart failure symptoms and reduce hospital visits for people with heart failure and obesity. This trial compares the new treatment to a placebo alongside standard care.

Heart FailureConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Buspirone for Weak Esophageal Motility

We are studying whether buspirone can improve swallowing and esophageal function in patients with poor motility. This trial compares the effects of buspirone to a placebo on symptoms and esophageal pressure measurements.

Ineffective Motility or Absent Peristalsis≤3 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesPartially RemoteGastroenterology

Multiple Sclerosis: Masitinib Treatment Study

We are investigating whether the oral medication masitinib is effective and safe for people with primary or secondary progressive multiple sclerosis without relapses. This study compares masitinib to a placebo to evaluate its impact on various symptoms and overall health.

Multiple Sclerosis1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteNeurology

Setmelanotide for ROHHAD Syndrome

We are studying the effects of setmelanotide on hypothalamic function and related symptoms in patients with ROHHAD syndrome. This trial aims to understand how the treatment may improve various health aspects over time.

ROHHAD Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Pulmonary Arterial Hypertension: Inhaled GB002 Study

We are evaluating the long-term safety and effects of an inhaled medication for people with pulmonary arterial hypertension. The study aims to see if it helps improve exercise capacity and overall well-being.

Pulmonary Arterial Hypertension>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Preventing Infections in ICU Patients with Interferon Gamma

We are studying whether interferon gamma can help prevent secondary infections in ICU patients with weakened immune systems. This research may improve recovery and reduce hospital stays.

Sustained Immunosuppression>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInfectious DiseasesInternal MedicinePulmonology

Diffuse Large B-Cell Lymphoma: Glofitamab with Gemcitabine and Oxaliplatin

We are studying a new treatment combination for patients with relapsed or refractory diffuse large B-cell lymphoma. The focus is on understanding the safety and frequency of cytokine release syndrome with this therapy.

Refractory Diffuse Large B-Cell Lymphoma6-12 monthsEfficacy phase (II)>20 visitsPartially RemoteHematologyOncology

Metastatic Non-Small Cell Lung Cancer: Visugromab Treatment

We are studying whether visugromab, combined with standard chemotherapy, can improve outcomes for patients with metastatic non-squamous non-small cell lung cancer. The trial also looks at safety and quality of life during treatment.

Metastatic Non-Squamous Non-Small Cell Lung CancerEfficacy phase (II)Investigational MedicinesPartially RemoteOncology

Metastatic Non-Squamous Non-Small Cell Lung Cancer: Visugromab and Nivolumab Study

We are investigating whether a new treatment combining visugromab and nivolumab with or without docetaxel can improve outcomes for patients with metastatic non-squamous non-small cell lung cancer. This study will help us understand its effectiveness and safety compared to standard treatments.

Metastatic Non-Squamous Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Investigational MedicinesPartially RemoteOncology

Metastatic Colorectal Cancer: Arfolitixorin Combination Therapy

We are studying a new treatment combining arfolitixorin with standard drugs for patients with metastatic colorectal cancer. The goal is to evaluate its safety and effectiveness in improving treatment results.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Parkinson's Disease: CVN424 Study

We are testing a new medication, CVN424, for people with Parkinson's disease to see if it helps reduce OFF time and improve overall motor function. The study also aims to evaluate its safety and effects on quality of life.

Parkinson's Disease3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology